Literature DB >> 10476010

Reversal of the sleep/wake cycle disorder of sleeping sickness after trypanosomicide treatment.

A Buguet1, P Tapie, J Bert.   

Abstract

To determine whether the circadian disruption of the sleep/wake cycle observed in sleeping sickness, human African trypanosomiasis (HAT), can be reversed after trypanosomicide treatment, 10 Congolese patients infected by Trypanosoma brucei gambiense underwent 24-h polysomnographic recordings before treatment with melarsoprol and after each of three weekly treatment sessions. Polysomnography consisted of a continuous recording of the electroencephalogram, electromyogram and electro-oculogram on a Minidix Alvar polygraph. Sleep traces were analysed in 20-sec epochs for wakefulness, REM sleep, and NREM sleep [stages 1, 2, 3, 4; stages 3 and 4 representing slow-wave sleep (SWS)]. As previously described (Buguet et al. 1993), the 24-h distribution of the sleep/wake cycle was disturbed proportionally to the severity of the illness. The overall amounts of each sleep/wake stage did not change after treatment. However, the patterns of occurrence of sleep episodes, REM sleep and SWS phases were determinant in the evaluation of treatment efficacy. The trypanosomicide action of melarsoprol led to a reduction in the number of sleep episodes, except in one patient whose health condition worsened during the third treatment session: sleep onset REM sleep phases (SOREMPs) decreased and the number of SWS episodes during a sleep episode increased. We conclude that in HAT, the reversibility of the sleep/wake cycle alteration and that of sleep structure constitute the basis for an evaluation of the healing process.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10476010     DOI: 10.1046/j.1365-2869.1999.00160.x

Source DB:  PubMed          Journal:  J Sleep Res        ISSN: 0962-1105            Impact factor:   3.981


  8 in total

Review 1.  Circadian rhythms in infectious diseases and symbiosis.

Authors:  Filipa Rijo-Ferreira; Joseph S Takahashi
Journal:  Semin Cell Dev Biol       Date:  2021-10-06       Impact factor: 7.499

2.  Actigraphy in human African trypanosomiasis as a tool for objective clinical evaluation and monitoring: a pilot study.

Authors:  Alfred K Njamnshi; Paul F Seke Etet; Stephen Perrig; Alphonse Acho; Julius Y Funsah; Dieudonné Mumba; Jean-Jacques Muyembe; Krister Kristensson; Marina Bentivoglio
Journal:  PLoS Negl Trop Dis       Date:  2012-02-14

3.  Sleeping sickness is a circadian disorder.

Authors:  Filipa Rijo-Ferreira; Tânia Carvalho; Cristina Afonso; Margarida Sanches-Vaz; Rui M Costa; Luísa M Figueiredo; Joseph S Takahashi
Journal:  Nat Commun       Date:  2018-01-04       Impact factor: 14.919

4.  Neural Damage in Experimental Trypanosoma brucei gambiense Infection: Hypothalamic Peptidergic Sleep and Wake-Regulatory Neurons.

Authors:  Claudia Laperchia; Yuan-Zhong Xu; Dieudonné Mumba Ngoyi; Tiziana Cotrufo; Marina Bentivoglio
Journal:  Front Neuroanat       Date:  2018-02-27       Impact factor: 3.856

5.  Neural Damage in Experimental Trypanosoma brucei gambiense Infection: The Suprachiasmatic Nucleus.

Authors:  Chiara Tesoriero; Yuan-Zhong Xu; Dieudonné Mumba Ngoyi; Marina Bentivoglio
Journal:  Front Neuroanat       Date:  2018-02-13       Impact factor: 3.856

Review 6.  Sleeping Sickness: A Tale of Two Clocks.

Authors:  Filipa Rijo-Ferreira; Joseph S Takahashi
Journal:  Front Cell Infect Microbiol       Date:  2020-10-02       Impact factor: 5.293

Review 7.  Sleep-Wake and Circadian Disorders after Tick-Borne Encephalitis.

Authors:  Gabriele Chiffi; Denis Grandgirard; Parham Sendi; Anelia Dietmann; Claudio L A Bassetti; Stephen L Leib
Journal:  Microorganisms       Date:  2022-01-27

8.  Morphological changes, nitric oxide production, and phagocytosis are triggered in vitro in microglia by bloodstream forms of Trypanosoma brucei.

Authors:  Katherine Figarella; Nestor L Uzcategui; Stefan Mogk; Katleen Wild; Petra Fallier-Becker; Jonas J Neher; Michael Duszenko
Journal:  Sci Rep       Date:  2018-10-09       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.